Nationwide Levothyroxine Recall Issued Over Potency Concerns
Federal regulators issued a Class II recall for levothyroxine, a widely used thyroid medication, on July 29, 2026. The recall was triggered by potency concerns that could affect how well the drug controls thyroid hormone levels. Patients were advised to contact their pharmacies.
Federal regulators issued a Class II recall for levothyroxine on July 29, 2026, citing concerns about the medication's potency, according to Healthline.
Levothyroxine is one of the most commonly prescribed drugs in the United States, used to treat hypothyroidism and other thyroid conditions. A Class II recall indicates that the product may cause temporary or medically reversible adverse health consequences.
The recall was triggered by testing that found potency levels outside the acceptable range. Medications with incorrect potency can fail to adequately control thyroid hormone levels, which may lead to symptoms such as fatigue, weight changes, or heart irregularities.
Regulators advised patients taking the affected lots to contact their pharmacies to determine whether their prescription was included in the recall. Patients were told not to stop taking their medication without consulting a doctor, as untreated hypothyroidism carries its own health risks.
The FDA and the manufacturer did not immediately release the full list of affected lot numbers in initial reports. Patients were directed to the FDA's recall database for updated information.
Levothyroxine recalls have occurred previously due to manufacturing inconsistencies. Doctors recommend that patients on thyroid medication have their levels checked regularly through blood tests.
